Basic Information
| LncRNA/CircRNA Name | HULLK |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | prostate cancer |
| ICD-0-3 | C61.9 |
| Methods | qPCR, Western blot |
| Sample | LNCaP and C4-2 cells, CWR22Rv1 (Rv1), VCaP, PC3, WMPY1(ATCC), MCF7, BT549 and MDA-MB-231, DU145, PANC1, HeLa, Jurkat, LHS, RWPE-1, FFPE PCa tissue, normal prostate tissue |
| Expression Pattern | up-regulated |
| Function Description | a previously unannotated lncRNA lying within exon six and 3`UTR of the LCK gene was dramatically upregulated by androgen in a dose-dependent manner, and the anti-androgen enzalutamide completely blocked this hormone-induced increase. Therefore, we labeled this lncRNA ??ULLK??for Hormone-Upregulated lncRNA within LCK. Binding sites for two AR coregulators p300 and Brd4 reside near the HULLK transcriptional start site (TSS), and inhibitors of these coregulators downregulated HULLK. HULLK is transcribed from the sense strand of DNA, and predominantly localizes to the cytoplasm. HULLK transcripts are not only expressed in prostate cancer cell lines, but also prostate cancer patient tissue. Remarkably, there was a significant positive correlation between HULLK expression and high-grade PCa in multiple cohorts. shRNAs targeting HULLK significantly decreased PCa cell growth. Moreover, cells overexpressing HULLK were hypersensitive to androgen stimulation. |
| Pubmed ID | 31253147 |
| Year | 2019 |
| Title | Discovery of a novel long noncoding RNA overlapping the LCK gene that regulates prostate cancer cell growth |
External Links
| Links for HULLK | GenBank HGNC NONCODE |
| Links for prostate cancer | OMIM COSMIC |